Acorda Therapeutics, Inc. v. Alkermes plc

CourtDistrict Court, S.D. New York
DecidedAugust 4, 2023
Docket1:23-cv-00223
StatusUnknown

This text of Acorda Therapeutics, Inc. v. Alkermes plc (Acorda Therapeutics, Inc. v. Alkermes plc) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Acorda Therapeutics, Inc. v. Alkermes plc, (S.D.N.Y. 2023).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK ---------------------------------------X

ACORDA THERAPEUTICS, INC,

Petitioner, MEMORANDUM AND ORDER - against - 23 Civ. 223 (NRB) ALKERMES PLC,

Respondent.

---------------------------------------X NAOMI REICE BUCHWALD UNITED STATES DISTRICT JUDGE

Petitioner Acorda Therapeutics, Inc. (“petitioner” or “Acorda”) brings this petition under the Convention for the Recognition and Enforcement of Foreign Arbitral Awards of June 10, 1958 (the “New York Convention”), 21 U.S.T. 2517, 330 U.N.T.S. 38, and the Federal Arbitration Act (“FAA”), 9 U.S.C. §§ 10-12, 201- 208, to confirm in part and modify in part an award of $16,554,267 plus interest and costs (the “Award”) issued in an arbitration between Acorda and Alkermes PLC (“respondent” or “Alkermes”). See ECF No. 1 (“Pet.”). While Acorda believes that the Tribunal’s “core rulings were indisputably correct” and should be confirmed, Acorda claims that the Tribunal manifestly disregarded the law in its damages analysis, resulting in an improper damages reduction of $65,629,716. See ECF No. 3 (“Pet. Br.”) at 7. For the reasons stated below, Acorda’s petition to modify the Award in part is denied and the Award is confirmed in its entirety. BACKGROUND A. Factual Background 1. Dispute Concerning Royalty Payments This case arises from a dispute concerning royalty payments owed under two agreements -- the Amended and Restated License

Agreement (the “License Agreement”) and the Supply Agreement (collectively, the “Agreements”) -- between Acorda and Elan Corporation, PLC, the predecessor in interest to Alkermes, which were executed in 2003. See Pet. ¶ 9; ECF Nos. 6-2, 6-3. Acorda is the developer of Ampyra, a medication to improve walking in people with multiple sclerosis. See Pet ¶ 9. Alkermes was the owner of the now-expired patent, U.S. Patent No. 5,540,938 (the “’938 Patent”), “which covered the sustained release of dalfampridine, the active pharmaceutical ingredient in Ampyra.” Pet ¶ 10. Pursuant to the Agreements, Alkermes agreed to license the ’938 Patent to Acorda and manufacture Ampyra exclusively for Acorda. Pet ¶¶ 9, 10. In exchange, Acorda agreed to pay Alkermes

a “specified royalty rate” of 18 percent and to “purchase a minimum percentage of Ampyra from Alkermes.” Pet ¶ 9. The 18 percent royalty rate was split between the License Agreement, which provided for a 10 percent royalty, and the Supply Agreement, which provided for an 8 percent royalty. See Pet. Br. at 10. After the ’938 Patent expired in July 2018, Acorda contended that “the expiration of the ’938 Patent, at the very least, altered the Agreements’ royalty provisions” and “therefore sought a reduction in the price it was paying to Alkermes for future orders of Ampyra.” See Pet ¶ 11. Alkermes disagreed. See Pet. Br. at 10. However, Acorda never terminated the Agreements and continued to pay royalties to Alkermes without protest until July 2020. See

id. at 8. At that point, Acorda formally objected to its ongoing royalty charges under the License Agreement on the basis that those payments violated Brulotte v. Thys Co., 379 U.S. 29 (1964), which held that post-expiry patent leveraging is improper. See id. at 6, 11; ECF No. 20 (“Resp. Opp.”) at 7. Acorda’s objection did not reference the Supply Agreement. See Resp. Opp. at 7. 2. The Arbitration i. Pleadings On July 28, 2020, Acorda commenced arbitration proceedings against Alkermes in the American Arbitration Association’s (“AAA”) International Centre for Dispute Resolution (“IDCR”) Tribunal in New York, New York. See Pet. ¶¶ 16, 18. The Tribunal consisted

of three distinguished, retired judges: the Honorable Robert S. Smith, the Honorable Arthur J. Gajarsa, and the Honorable Jose L. Linares. See id. ¶ 18; ECF No. 6-1 (the “Award”) at 2; Resp. Opp. at 7. Acorda asserted claims for: “(1) declaratory judgment as to whether Alkermes was entitled to patent-licensing royalties after the ’938 Patent expired on July 30, 2018; (2) declaratory judgment as to whether Alkermes was entitled to supply royalties above a fair market rate after July 30, 2018; (3) declaratory relief as to a return of overpayment; (4) unjust enrichment by retaining overpayment; (5) breach of the License Agreement; (6) monopolization in violation of Section 2 of the Sherman Act

and the Donnelly Act; (7) attempted monopolization in violation of Section 2 of the Sherman Act and the Donnelly Act; and (8) breach of the implied covenant of good faith and fair dealing.” Pet. ¶ 16. “Acorda sought a ruling from the Tribunal that Alkermes’s ongoing royalty charges violated [Brulotte] . . . and that, as a result, Acorda is entitled to a refund of all royalties paid after the expiration of the ’938 Patent.” Pet. ¶ 16. On August 17, 2020, Alkermes filed an answer, requesting that the Tribunal deny Acorda’s claims. Pet. ¶ 17. Alkermes later filed an amended answer, in which it raised two counterclaims: “(1) correction of inventorship pursuant to 35 U.S.C. § 256; and (2) a declaratory judgment that the unexpired patents must be

assigned to Alkermes.” Id. ii. Motion Practice The parties engaged in extensive motion practice in advance of an evidentiary hearing. Acorda filed motions to dismiss Alkermes’ counterclaims and for an order permitting all future royalty payments to be held in escrow. See Pet. ¶ 19; Award at 4. After those motions were fully briefed and oral argument was held, the Tribunal granted Acorda’s motion to dismiss Alkermes’ counterclaims and denied Acorda’s motion to hold future payments in escrow. See Award at 5. Subsequently, the parties engaged in discovery, which was completed on July 23, 2021. See Pet. ¶ 19. The parties then filed six motions for summary judgment, which

were fully briefed on November 23, 2021. See Pet. ¶ 20. Following oral argument, the Tribunal issued a decision on April 11, 2022 regarding the summary judgment motions, which “(1) dismissed Acorda’s claims for breach of contract and breach of the implied covenant of good faith and fair dealing; (2) denied Alkermes’s motion as to Acorda’s unjust enrichment/restitution claims; (3) denied Acorda’s affirmative motion as to its claims for monopolization and attempted monopolization; and (4) granted Alkermes’s motion as to Acorda’s claims for monopolization and attempted monopolization.” Pet. ¶ 21; see also Award at 5-6. In their decision, the Tribunal held that any recovery obtained by Acorda in connection with their claims of unjust enrichment and

restitution would be limited to the recovery of royalty payments made after Acorda formally raised its Brulotte objection to Alkermes. See Pet. ¶ 23; ECF No. 6-5 (“SJ Opinion”) at 7. In so holding, the Tribunal pointed to a “no-refund” clause in the Agreements, and noted that, due to the existence of the clause, it need not address Alkermes’ additional argument that the New York Voluntary Pay Doctrine (“NYVPD”) prevents Acorda from seeking a return on the payments it made between July 2018 and July 2020. See SJ Opinion at 11-14. In pre-hearing briefing, Acorda argued that the Tribunal’s limitation on its requested recovery was improper because, if the Tribunal found that a Brulotte violation occurred, then the

Agreements would be rendered unenforceable and all improper royalty payments made after the ’938 Patent expired would be recoverable. See Pet. ¶ 25. After Alkermes responded and Acorda filed a reply, see Pet.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Brulotte v. Thys Co.
379 U.S. 29 (Supreme Court, 1964)
Kaiser Steel Corp. v. Mullins
455 U.S. 72 (Supreme Court, 1982)
Bonito Boats, Inc. v. Thunder Craft Boats, Inc.
489 U.S. 141 (Supreme Court, 1989)
Hall Street Associates, L. L. C. v. Mattel, Inc.
552 U.S. 576 (Supreme Court, 2008)
Blair & Co., Inc. v. Gottdiener
462 F.3d 95 (Second Circuit, 2006)
Zeiler v. Deitsch
500 F.3d 157 (Second Circuit, 2007)
Zila, Inc. v. Tinnell
502 F.3d 1014 (Ninth Circuit, 2007)
T. CO METALS, LLC v. Dempsey Pipe & Supply, Inc.
592 F.3d 329 (Second Circuit, 2010)
Telenor Mobile Communications AS v. STORM LLC
584 F.3d 396 (Second Circuit, 2009)
Josephthal & Co., Inc. v. Cruttenden Roth Inc.
177 F. Supp. 2d 232 (S.D. New York, 2001)
Kimble v. Marvel Entertainment, LLC
135 S. Ct. 2401 (Supreme Court, 2015)
Dillon v. U-A Columbia Cablevision of Westchester, Inc.
292 A.D.2d 25 (Appellate Division of the Supreme Court of New York, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
Acorda Therapeutics, Inc. v. Alkermes plc, Counsel Stack Legal Research, https://law.counselstack.com/opinion/acorda-therapeutics-inc-v-alkermes-plc-nysd-2023.